Important Information for Shareholders
- High Exposure to Quoted Securities: The Group’s aggregate cost of quoted investments is notably high at over 2.5 times its latest audited net tangible assets. This may indicate a significant exposure to market risk, which could impact the Group’s financial position and share price, especially if market values continue to diverge from acquisition costs.
- Potential Price Sensitivity: The scale of both acquisitions and disposals, along with the high investment exposure, is material and could affect investor sentiment and share price — particularly if there is further volatility in the value of these quoted securities.
- Financial Health Indicator: Shareholders should note the declining market value of quoted investments despite fresh acquisitions, which may suggest unrealized losses or challenging market conditions for the Group’s investment portfolio.
- Regulatory Compliance: These announcements are made in compliance with Singapore Exchange Mainboard Listing Manual Rules 704(17)(b) and 704(18)(b), underscoring the materiality of these transactions.
Detailed Breakdown
| Before Acquisition | After Acquisition | |
|---|---|---|
| Aggregate cost of quoted investments (S\$’000) | 347,065 | 348,774 |
| As % of audited consolidated net tangible assets (NTA) (S\$139,142,000) | 249.4% | 250.7% |
| Total market value of quoted investments (S\$’000) | 243,747 | 242,386 |
| Provision for diminution in value (S\$’000) | – | – |
Conclusion
The announcement by mDR Limited highlights significant transactions in quoted securities, reflecting a strategic shift or rebalancing of its investment portfolio. The high exposure to quoted securities, combined with a slight decline in market value, may be of concern to investors as it introduces market volatility risk. Shareholders are advised to monitor further updates closely, as these developments could have a material impact on the Group’s financial performance and share price.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors are encouraged to consult their professional advisors before making any investment decisions based on this report.
mDR有限公司公布有关上市证券的重要交易
公告要点
- 重大买卖上市证券：2026年3月24日至2026年5月26日期间，mDR有限公司（“公司”）及其子公司（“集团”）共计购买上市证券约1,368.35万新元，相当于集团最新经审计净有形资产的9.8%。同期，集团以历史成本计出售上市证券约1,127.77万新元，占净有形资产的8.1%。
- 投资组合影响：交易后，集团上市投资的总成本小幅上升，从3.47065亿新元增至3.48774亿新元，占2025年12月31日净有形资产（1.39142亿新元）的比例由249.4%升至250.7%。
- 投资市值变化：交易后，上市投资的总市值从2.43747亿新元略降至2.42386亿新元，显示可能存在未实现损失或市场波动。
- 无减值准备：本期内未对上市投资计提减值准备。
股东需关注的重要事项
- 高比例投资风险：集团上市证券投资成本已超过最新经审计净有形资产的2.5倍，显示高度市场风险敞口，若市值进一步下跌，可能对集团财务状况和股价带来影响。
- 价格敏感事项：本次大规模买卖及高投资敞口属于重大事项，如市场出现波动，或将影响投资者情绪及公司股价。
- 财务健康警示：投资市值在大量买入后反而下跌，可能预示存在未实现亏损或市场环境不佳，需引起股东关注。
- 合规披露：本次公告根据新交所主板上市手册规则704(17)(b)及704(18)(b)作出，显示事项重大性。
详细数据
| 交易前 | 交易后 | |
|---|---|---|
| 上市投资总成本（千新元） | 347,065 | 348,774 |
| 占净有形资产比重（1.39142亿新元） | 249.4% | 250.7% |
| 上市投资总市值（千新元） | 243,747 | 242,386 |
| 减值准备（千新元） | – | – |
结论
mDR有限公司的公告反映了其在上市证券投资组合上的重大变动。高敞口及市值下滑风险值得投资者关注。建议股东密切关注后续信息，此类变动有可能对公司财务及股价造成重大影响。
免责声明
本文仅供参考，不构成投资建议。投资者应咨询专业顾问后再做出投资决策。
